摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(oxetan-3-yl)phthalazin-1(2H)-one | 1180653-77-3

中文名称
——
中文别名
——
英文名称
4-(oxetan-3-yl)phthalazin-1(2H)-one
英文别名
4-(oxetan-3-yl)-2H-phthalazin-1-one
4-(oxetan-3-yl)phthalazin-1(2H)-one化学式
CAS
1180653-77-3
化学式
C11H10N2O2
mdl
——
分子量
202.213
InChiKey
CQMFUXWOJZIWIE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    3-碘氧杂环丁烷1-甲氧基二氮杂萘ferrous(II) sulfate heptahydrate硫酸双氧水 作用下, 以 二甲基亚砜 为溶剂, 以34%的产率得到4-(oxetan-3-yl)phthalazin-1(2H)-one
    参考文献:
    名称:
    Preparation of Heteroaryloxetanes and Heteroarylazetidines by Use of a Minisci Reaction
    摘要:
    Introduction of oxetan-3-yl and azetidin-3-yl groups into heteroaromatic bases was achieved by using a radical addition method (Minisci reaction). To demonstrate utility. the process was used to introduce an oxetane Or azetidine into heteroaromatic systems that have found important uses in the drug discovery industry, such as the marketed EGFR inhibitor geftinib, a quinolinecarbonitrile Src tyrosine kinase inhibitor, and the antimalarial hydroquinine.
    DOI:
    10.1021/jo9010624
点击查看最新优质反应信息

文献信息

  • Preparation of Heteroaryloxetanes and Heteroarylazetidines by Use of a Minisci Reaction
    作者:Matthew A. J. Duncton、M. Angels Estiarte、Russell J. Johnson、Matthew Cox、Donogh J. R. O’Mahony、William T. Edwards、Michael G. Kelly
    DOI:10.1021/jo9010624
    日期:2009.8.21
    Introduction of oxetan-3-yl and azetidin-3-yl groups into heteroaromatic bases was achieved by using a radical addition method (Minisci reaction). To demonstrate utility. the process was used to introduce an oxetane Or azetidine into heteroaromatic systems that have found important uses in the drug discovery industry, such as the marketed EGFR inhibitor geftinib, a quinolinecarbonitrile Src tyrosine kinase inhibitor, and the antimalarial hydroquinine.
查看更多